The evolving and dynamic pharmaceutical industry faces numerous challenges and opportunities. One of the most critical aspects of drug development and safety is Pharmacovigilance. With digital technologies coming to fore, the transformation in Pharmacovigilance has to happen. Pharmacovigilance has always been backed with data collection and analysis, which is time consuming and resource exhaustive. The arduous volume of data generated through various sources has saturated existing Pharmacovigilance systems.
The digitalization enables real time monitoring and with use of algorithms not only vast data sets are analysed but quick detection of signals are allowed. This helps improving data preciseness thus reducing human error. Artificial Intelligence can assist adverse events based on retrospective data on patient profiles. This allows for risk mitigation as a proactive rather than a reactive approach. Reporting events through data apps not only promote patient centric approach but even facilitate patient engagement and participation on a regular basis. There is more data sharing among different stakeholders at various levels thus giving more visibility to all. Overall, Pharma industry regulatory compliance gets even more compliant to changing landscape. With Digitalization, one has to be wary of data privacy; hence better framework especially in doing investment and careful program planning is needed to carry out execution in future
In order to improve patient safety, digitalization will hold an immense advantage. It is more of a necessity now to embrace digitalization in Pharmacovigilance industry by promoting collaboration and awareness among stakeholders through better quality data and gaining vying advantage.
Comments